GlassScriptPhysician profile
Trisha Khanna
NPI 1427554203
$2,067.27
in general payments reported to CMS, 2019-2025
20 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $166 · 2021: $233 · 2022: $204 · 2023: $371 · 2024: $664 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.86 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $318.01 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $290.31 | 2023-2024 | |
| Genentech USA, INC. | $250.00 | 2019 | |
| Revance Therapeutics, INC. | $221.48 | 2024-2025 | Daxxify |
| Sun Pharmaceutical Industries INC. | $197.79 | 2021-2024 | Ilumya, Odomzo, Blu-U |
| Dermavant Sciences, INC. | $197.02 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $175.03 | 2020-2025 | Dupixent, Libtayo |
| Amgen INC. | $115.05 | 2021-2025 | Otezla |
| Incyte Corporation | $48.53 | 2022-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $44.52 | 2020 | |
| Leo Pharma INC. | $42.80 | 2022-2023 | Adbry |
| Organogenesis INC. | $32.95 | 2025 | Affinity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.49 | 2023 | Spevigo |
| Boston Scientific Corporation | $22.70 | 2023 | Varithena Administration Pack |
| Pfizer INC. | $21.02 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $17.86 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.14 | 2023 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $16.52 | 2023 | |
| Mayne Pharma Commercial LLC | $13.05 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Khanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.